One Case of Vitiligo Caused by Sintilimab Injection in a Patient with Advanced Long-Term Survival Lung Adenocarcinoma

doi:10.19803/j.1672-8629.20240760

Abstract

Abstract: Objective To investigate the relationship between the occurrence of vitiligo and the clinical benefits of programmed cell death-1(PD-1)/ programmed cell death-ligand 1(PD-L1) inhibitors in order to provide a reference for clinical safety and monitoring of Adverse Drug Reactions. Methods One case of vitiligo induced by sintilimab in a patient with pulmonary adenocarcinoma was analyzed. Case reports of vitiligo caused by PD-1/PD-L1 inhibitors collected between January 1, 2000 and September 1, 2024 were retrieved from PubMed, Web of Science and CNKI full-text databases. Descriptive statistical analysis was performed. Results The patient developed vitiligo 33 months after usingPD-1 inhibitors. The correlation between clinical manifestations and the duration of medication suggested that vitiligo was likely to be caused by sintilimab. Based on the literature review, a total of 20 patients were included in the analysis. The earliest onset was one month after immunotherapy with PD-1/PD-L1 inhibitors, and the longest one 20 months later. Fifteen cases occurred within 3 to 8 months of immunotherapy. Conclusion Clinicians who prescribe PD-1/PD-L1 inhibitors should be alert to the risk of vitiligo. The occurrence of vitiligo may be closely related to the good prognosis of immunotherapy.

Key words: Sintilimab, Vitiligo, Adenocarcinoma of Lungs, Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Adverse Drug Reactions

CLC Number:

LIU Yalan, LIU Yanxiang, CHEN Peng. One Case of Vitiligo Caused by Sintilimab Injection in a Patient with Advanced Long-Term Survival Lung Adenocarcinoma[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 460-462.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240760

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I4/460

References

[1] FRISOLE ML, ESSIEN K, HARRIS JE, et al.Vitiligo: Mechanisms of Pathogenesis and Treatment[J]. Annu Rev Immunol, 2020, 26(38): 621-648.
[2] WILKINS MC, ELGAMAL M, RYBKIN II, et al.Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient with Durable Complete Response[J]. Cureus, 2021, 13(11): e19739.
[3] RKMAN D, ROBERT L, MARKO B, et al.Skin Autoimmunity Might be Associated with Increased Efficacy of Atezolizumab in Metastatic Urothelial Carcinoma: a Case Report[J]. Croat Med J, 2019, 60(6): 552-555.
[4] MARIA LC, GABRIELE M, ALESSIA C, et al.Vitiligo-Specific Soluble Biomarkers as Early Indicators of Response to Immune Checkpoint Inhibitors in Metastatic Melanoma Patients[J]. Sci Rep, 2022, 12(1): 5448.
[5] EMILY SY, MARIAM BT, JONATHAN SL, Nivolumab-Associated Vitiligo-Like Depigmentation in a Patient with Acute Myeloid Leukemia: a Novel Finding[J]. JAAD Case Rep, 2017, 3(2): 90-92.
[6] TAISUKE M, YASUHIRO N, SHIGETO M, et al.Vitiligo Expansion and Extent Correlate with Durable Response in Anti-Programmed Death 1 Antibody Treatment for Advanced Melanoma: a Multi-Institutional Retrospective Study[J]. J Dermatol, 2020, 47(6): 629-635.
[7] SOFIA V, FRANCESCA RD, SIMONA M, et al.Vitiligo-Like Leukoderma as an Indicator of Clinical Response to Immune Checkpoint Inhibitors in Late-Stage Melanoma Patients[J]. J Cancer Res Clin Oncol, 2022, 148(9): 2529-2538.
[8] VEDRANA B, ROBERT L, LADA B, et al.Pembrolizumab-Induced Vitiligoin a Patient with Lung Adenocarcinoma: a Case Report[J]. Br J Clin Pharmacol, 2021, 87(6): 2614-2618.
[9] INIGO NF, CARMEN GV, CRISTINA GF, et al.Vitiligo-Like Depigm-entation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-Cell Carcinoma[J]. Acta Dermatovenerol Croat, 2021, 291(1): 54-55.
[10] SOOK JY, IN JO, CHEOL KP, et al.Vitiligo-Like Depigmentation after Pembrolizumab Treatment in Patients with Non-Small Cell Lung Cancer: a Case Report[J]. Transl Lung Cancer Res, 2020, 9(4): 1585-1590.
[11] WANG JJ, LIU BH, TU QB, et al.Chinese and Western Pharmaceutical Care and Literature Review of a Case of Camrelizumab Induced Vitiligo[J]. Central South Pharmacy, 2024, 22(9): 2535-2539.
[12] RAO H, ZENG XL, HUANG L, et al.PD-1 Inhibitor Induced Vitiligo-Like Depigmentation in Gastric Cancer: a Case Report and Systematic Review of the Literature[J]. Modern Medical Oncology, 2023, 31(13): 2502-2504.
[13] ZHANG JJ, WU J, DAI XJ, et al.Vitiligo-Like Leukoderma Following Toripalimab Therapy for a Patient with Melanoma: a Case Report[J]. Chinese Journal of Dermatology and Venereology, 2023, 37(11): 1314-1316.
[14] WANG LY, SUN YY, JIANG JJ.Camrelizumab Induced Vitiligo: a Case Report[J]. Chinese Journal of Modern Applied Pharmacology, 2022, 39(24): 3308-3309.
[15] ZHANG C, TAO Y HU JL, et al. A Case of Vitiligo Induced by Sintilimab Injection[J]. Chinese Journal of Modern Applied Pharmacy, 2021, 38(19): 2431-2432.
[16] ZHU WT, WU X, ZHANG XH, et al.Long-Term Survival of Patients with Advanced Lung Squamous Cell Carcinoma Complicated by Vitiligo after Treatment with PD-1 Monoclonal Antibody[J]. Cancer Progress, 2018, 16(13): 1688-1689.
[17] AYESHA S, WARSHA R, RABIA O, et al.FDA Approves Ruxolitinib (Opzelura) for Vitiligo Therapy: a Breakthrough in the Field of Derma-tology[J]. Ann Med Surg (Lond), 2022, 28(81): 104499.
[18] LUIS GV, LUIS L, JORGE AA, et al.Phimosis: a Rare Complication of Immunotherapy with Durvalumab[J]. Urol Case Rep, 2020, 16(33): 101350.
[19] FRANZISKA G, KATHARINA E, SOPHIA M, et al.Vitiligo-Like Lesions Developing upon Immune Checkpoint Inhibition in Advanced Melanoma[J]. Eur J Dermatol, 2020, 30(1): 72-73.
[20] THOMAS KL, ISABELLE B, REBECCA G, et al.Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: an Observational, Pharmacovigilance Study[J]. J Invest Dermatol, 2022, 142(11): 2896-2908e4.
[21] CHRISTINE L, STEPHANIE RC, SARAH A, et al.Vitiligo Adverse Events and Associated Medications as Reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021[J]. J Am Acad Dermatol, 2023, 88(1): 197-199.
[22] MARIA LC, ALESSIA C, MARIKA G, et al.Insight into Immune Profile Associated with Vitiligo Onset and Anti-Tumoral Response in Melanoma Patients Receiving Anti-PD-1 Immunotherapy[J]. Front Immunol, 2023, 23(14): 1197630.
[23] FUKUDA K.Networks of CD8(+) T Cell Response Activation in Melanoma and Vitiligo[J]. Front Immunol, 2022, 1(13): 866703.
[24] LINDSAY MC, LEAH LT, MICHAEL SC, et al.Cutaneous Adverse Events to Immune Checkpoint Inhibitors in Pediatric Populations: a Retrospective Cohort Study[J]. J Am Acad Dermatol, 2021, 85(6): 1587-1589.